Roohi-Azizi Mahtab, Arabzadeh Somaye, Amidfar Meysam, Salimi Samrand, Zarindast Mohammad Reza, Talaei Ali, Akhondzadeh Shahin
*Department of Neurosciences, School of Advanced Medical Technologies; †Psychiatric Research Centre, Roozbeh Hospital; and ‡Baharloo Hospital, Tehran University of Medical Sciences, Tehran; and §Faculty of Medicine, Psychiatry and Behavioral Sciences Research Center, Mashad University of Medical Sciences, Mashad, Iran.
Clin Neuropharmacol. 2017 Jan/Feb;40(1):1-5. doi: 10.1097/WNF.0000000000000185.
Residual symptoms of major depressive disorder are a source of long-term morbidity. New therapeutic strategies are required to alleviate this morbidity and enhance patient quality of life. Citicoline has been used for vascular accidents and has been effective in cognitive rehabilitation. It has been used successfully to reduce craving in patients with substance abuse disorder and for mood management of bipolar disorder. Here, we test citicoline effectiveness as an adjuvant therapy in major depression.
A double-blind randomized trial was designed on 50 patients with major depressive disorder who were under treatment with citalopram. Patients were allocated to 2 groups and received citicoline (100 mg twice a day) or placebo as an adjuvant treatment for 6 weeks. Depressive symptoms were assessed by the Hamilton Depression Rating Scale (HDRS) at baseline and at weeks 2, 4, and 6.
Significantly greater improvement was observed in the HDRS scores of the citicoline group compared with the placebo group from baseline to weeks 2, 4, and 6 (Ps = 0.030, 0.032, and 0.021, respectively). Repeated-measures general linear model demonstrated a significant effect for time × treatment interaction on the HDRS score (F2.10,101.22 = 3.12, P = 0.04). Remission rate was significantly higher in the citicoline group compared with the placebo group (P = 0.045).
Citicoline was an effective adjuvant to citalopram in the therapy of major depressive disorder.
重度抑郁症的残留症状是长期发病的一个根源。需要新的治疗策略来减轻这种发病情况并提高患者生活质量。胞磷胆碱已用于治疗血管意外，且在认知康复方面有效。它已成功用于减少物质滥用障碍患者的渴望以及双相情感障碍的情绪管理。在此，我们测试胞磷胆碱作为重度抑郁症辅助治疗的有效性。
对50名正在接受西酞普兰治疗的重度抑郁症患者设计了一项双盲随机试验。患者被分为两组，接受胞磷胆碱（每日两次，每次100毫克）或安慰剂作为辅助治疗，为期6周。在基线以及第2、4和6周时，通过汉密尔顿抑郁量表（HDRS）评估抑郁症状。
从基线到第2、4和6周，与安慰剂组相比，胞磷胆碱组的HDRS评分有显著更大的改善（P值分别为0.030、0.032和0.021）。重复测量的一般线性模型显示时间×治疗交互作用对HDRS评分有显著影响（F2.10,101.22 = 3.12，P = 0.04）。与安慰剂组相比，胞磷胆碱组的缓解率显著更高（P = 0.045）。
在重度抑郁症治疗中，胞磷胆碱是西酞普兰的有效辅助药物。
